TICKERNERD
Menu
JAGXJAGXHealthcare · Biotechnology

JAGX Stock Forecast: Jaguar Health, Inc. Price Predictions for 2026-2027

Last close, 22 Oct 2026
$2.15

The 1 Wall Street analysts covering Jaguar Health, Inc. hold a median 12-month price target of $263 — +12109.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 63 of 100 as at 22 Oct 2026 — in the upper half.

Market cap
$4.2M
Ticker Nerd rank
63/ 100
Median analyst target
$263
Analysts covering
1
Revenue$1.2M−58.9% y/y
Operating income−$7.6M
Net income−$12.8M
Free cash flow−$5.3M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Ticker Nerd rank

JAGX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Jaguar Health, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Oct 2026
63/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
99
Growth
96
Size
96
Quality
53
Issuance
52
Value
48
Momentum
27
Revisions
25
Volatility
7

Accruals (99): Reported profit is backed by cash, and the company is not expanding recklessly.

Volatility (7): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

JAGX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on JAGX, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Low $263Median $263High $263

The green dot is the last close — the median target sits +12109.3% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
19 May 2025First BerlinInitiatesBuy$60
7 July 2021Cantor FitzgeraldInitiatesOverweight$5.00
25 Nov 2020Aegis CapitalInitiatesBuy—
25 Nov 2020H.C. WainwrightReiteratesBuy—
25 Nov 2020Ladenburg ThalmannInitiatesBuy—
25 Nov 2020Rodman & RenshawInitiatesBuy—
18 Nov 2019H.C. WainwrightReiteratesBuy—
18 Nov 2019HC Wainwright & Co.ReiteratesBuy$10 → $3.00
12 Sept 2019Ladenburg ThalmannInitiatesBuy—
11 July 2017Rodman & RenshawInitiatesBuy—
12 Nov 2015Aegis CapitalInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

JAGX appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.
  • The AI build-out, every Wednesday: how AI stocks did, part by part.

Free. Unsubscribe any time.

Estimates

JAGX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Jaguar Health, Inc. (JAGX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.0×

Cheaper than 75% of US stocks

Price / sales
0.2×

Cheaper than 94% of US stocks

Price / book
0.1×

Cheaper than 90% of US stocks

EV / EBITDA
−0.6×

Cheaper than 66% of US stocks

Growth & margins
Revenue growth (YoY)
−58.9%

Higher than 4% of US stocks

Earnings growth (YoY)
−58.9%

Higher than 9% of US stocks

Gross margin
15.8%

Higher than 15% of US stocks

Operating margin
−620.2%

Higher than 7% of US stocks

Net margin
−130.8%

Higher than 5% of US stocks

Returns & dividend
Return on equity
−548.8%

Higher than 3% of US stocks

Return on assets
−38.0%

Higher than 11% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Jaguar Health, Inc. (JAGX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Jaguar Health, Inc. has a market value of $4.2M and an enterprise value of $13.6M.

  • Revenue in the twelve months to 30 June 2026: $27.8M. The latest quarter shrank 58.9% year on year.

  • Net income over the same four quarters: −$36.9M, a −132.9% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$6.7M.

  • Shares outstanding: 4.9M.

  • Trailing P/E: 0.0×; forward P/E: −0.4× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Jaguar Health, Inc. employs 47 people — $591K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 23 Oct 2026

Data provided by Twelve Data

Peers

JAGX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
JAGXJaguar Health, Inc.$4.2M63
LIMNLiminatus Pharma, Inc.$4.2M16
DRMADermata Therapeutics, Inc.$4.3M33
AZTRAzitra, Inc.$4.3M39
ENLVEnlivex Ltd.$4.0M5
XBIOXenetic Biosciences, Inc.$4.5M27
NRSNNeurosense Therapeutics Ltd.$4.6M3

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Jaguar Health, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest JAGX news & analysis

Jaguar Health's Crofelemer Shows Benefit for Intestinal Failure (IF) in Third Rare Congenital Enteropathy Disorder

Accesswire · 21 Oct 2026positive

Jaguar Health said crofelemer oral therapy has been provided to an infant with GUCY2C-mutation-related congenital sodium diarrhea for several weeks. The company reported the treatment was well tolerated and reduced the patient’s daily and weekly parenteral support needs, with no significant clinical or laboratory abnormalities.

Why it matters — The report adds GUCY2C-related congenital enteropathy to the conditions for which Jaguar says crofelemer has demonstrated benefit in reducing pediatric patients’ parenteral support needs.

Jaguar Health Provides Update Regarding Special Stock Dividend

Accesswire · 14 Oct 2026neutral

Jaguar Health said Nasdaq set October 16, 2026, as the ex-dividend date for its special dividend of Series R Convertible Preferred Stock, payable October 15 to eligible holders of common stock and certain warrants of record October 13. The company said the dividend is intended to provide dilution protection while it evaluates strategic alternatives.

Why it matters — JAGX shareholders and eligible warrant holders may want to note the dividend dates and Jaguar’s stated intent for the distribution.

Positive Preliminary Results Presented at Annual American College of Gastroenterology Meeting for Open-Label Study in Adult Short Bowel Syndrome Patients with Intestinal Failure (SBS-IF) with Jaguar Health's Crofelemer

Accesswire · 14 Oct 2026positive

Napo Pharmaceuticals recapped positive preliminary results, presented October 13 at the ACG 2026 meeting, from its ongoing open-label pilot study of crofelemer powder for oral solution in adults with Type 1 short bowel syndrome and intestinal failure.

Why it matters — The presentation concerns Jaguar's crofelemer development program for rare intestinal-failure diseases, including SBS-IF.

Reminder: Today, October 13, 2026, is the Record Date for Jaguar Health's Special Stock Dividend

Accesswire · 13 Oct 2026neutral

Jaguar Health reminded shareholders that October 13, 2026, is the record date for its special stock dividend, which was declared for holders of common stock and certain outstanding warrants. The company said the dividend is intended to provide dilution protection as it evaluates strategic alternatives.

Why it matters — JAGX investors may want to note the record date and the company’s stated purpose for the dividend, alongside its expected clinical milestones for crofelemer.

Napo Pharmaceuticals, a Jaguar Health Family Company, Sponsoring Intestinal Failure Panel Discussion at Pediatric Gastroenterology Conference in Abu Dhabi

Accesswire · 6 Oct 2026neutral

Jaguar Health said its family company Napo Pharmaceuticals is sponsoring the 2nd Best of Elite Ped-GI meeting in Abu Dhabi and a panel on intestinal barriers beyond total parenteral nutrition on October 30, 2026. Panel participants include three clinicians and Jaguar and Napo Chief Scientific Officer Pravin Chaturvedi.

Why it matters — The event relates to Jaguar’s rare-disease intestinal failure program for MVID and short bowel syndrome, including crofelemer powder development.

FAQ

Frequently asked questions about JAGX stock

What is the JAGX stock price forecast for 2026-2027?

The 1 Wall Street analysts covering Jaguar Health, Inc. have a median 12-month price target of $263, with estimates ranging from $263 to $263. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is JAGX stock a buy right now?

Of the 1 analysts covering Jaguar Health, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Jaguar Health, Inc. 63 out of 100 across roughly 4,600 US stocks as at 22 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank JAGX?

As at 22 Oct 2026, Jaguar Health, Inc. ranks 63 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (99 of 100).

Will JAGX stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +12109.3% from the last close, and Ticker Nerd's factor model ranks Jaguar Health, Inc. 63 out of 100 as at 22 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the JAGX stock forecast for 2030?

No analyst covering Jaguar Health, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for JAGX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $263 to $263 over the next 12 months.

What does Jaguar Health, Inc. do?

Jaguar Health, Inc. is a commercial-stage pharmaceuticals company focused on developing and commercializing plant-based gastrointestinal products for humans and animals.

What is the latest news on JAGX?

The most recent item we track (Accesswire, 21 Oct 2026): "Jaguar Health's Crofelemer Shows Benefit for Intestinal Failure (IF) in Third Rare Congenital Enteropathy Disorder". Jaguar Health said crofelemer oral therapy has been provided to an infant with GUCY2C-mutation-related congenital sodium diarrhea for several weeks. The company reported the treatment was well tolerated and reduced the patient’s daily and weekly parenteral support needs, with no significant clinical or laboratory abnormalities.

Company

About Jaguar Health, Inc.

Jaguar Health, Inc. is a commercial-stage pharmaceuticals company focused on developing and commercializing plant-based gastrointestinal products for humans and animals. Its current business is organized around two segments, Human Health and Animal Health, covering prescription and non-prescription products for conditions such as chronic diarrhea, bowel urgency, and related gastrointestinal distress. The company’s human portfolio includes therapies for HIV-related diarrhea and other gastrointestinal indications, while its animal health activities target companion and production animals with digestive health needs. Jaguar Health also works through its subsidiaries to support proprietary products derived from sustainably sourced botanical ingredients. Headquartered in San Francisco, California, Jaguar Health plays a specialized role in the pharmaceutical market by addressing gastrointestinal disorders across both human and veterinary care.

CEO Ms. Lisa A. Conte · 47 employees · United States · https://jaguar.health